Price movement over the last 24 hours
Alcon AG vs DraftKings Inc — how do they compare? Alcon AG trades at $66.95 (market cap $32.69B), while DraftKings Inc trades at $26.31 (market cap $13.35B). The key difference: Alcon AG is far larger — about 2.4× DraftKings Inc's market cap, and Alcon AG pays a 0.54% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| ALC | DKNG | |
|---|---|---|
Market Cap | $32.69B | $13.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $48.23 |
52-Week Low | $62.02 | $20.72 |
Enterprise Value | $36.28B | $14.27B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
DraftKings (DKNG) trades at $26.91, up 3.94% today, with a bearish technical signal but strong analyst consensus. Revenue grew to $6.05B in 2025, achieving positive net income of $3.71M, a significant turnaround from prior losses. The launch of the DKeX prediction market exchange (Business Wire, 2026-06-26) and record sportsbook engagement during the 2026 World Cup (Benzinga, 2026-06-26) highlight growth initiatives, though profitability remains thin with a P/E of 291.22.
The outlook is mixed: robust revenue growth and a $34.25 analyst price target suggest upside, but high valuation, competitive pressures, and regulatory risks pose challenges. Positive cash flow from operations of $662.86M in 2025 supports stability, yet volatility near key resistance at $27 requires monitoring for sustained bullish momentum.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →